Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data-Reference-Cited by-同舟云学术

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data

Published:2019-12-04 Issue:2 Volume:9 Page:626-639
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Goto Daisuke¹^ORCID,Khairnar Rahul²^ORCID,Yared Jean A.³^ORCID,Yong Candice⁴^ORCID,Romanus Dorothy⁵^ORCID,Onukwugha Eberechukwu²,Slejko Julia F.²^ORCID

Affiliation:

1. Merck Research Laboratories North Wales PA USA

2. Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USA

3. Department of Medicine University of Maryland School of Medicine Baltimore MD USA

4. AstraZeneca Pharmaceuticals LP Gaithersburg MD USA

5. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2698

Reference47 articles.

1. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction

2. Current and Emerging Treatments for Multiple Myeloma

3. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

4. Racial disparities in incidence and outcome in multiple myeloma: a population-based study

5. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Language Processing Algorithm to Extract Multiple Myeloma Stage From Oncology Notes in the Veterans Affairs Healthcare System;JCO Clinical Cancer Informatics;2024-07

2. Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review;Clinical Lymphoma Myeloma and Leukemia;2023-11

3. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma;Future Oncology;2023-04

4. Association of individual low-income status and area deprivation with mortality in multiple myeloma;Journal of Geriatric Oncology;2023-03

5. Multisite Quality Improvement Initiative to Identify and Address Racial Disparities and Deficiencies in Delivering Equitable, Patient-Centered Care for Multiple Myeloma—Exploring the Differences between Academic and Community Oncology Centers;Current Oncology;2023-01-25